Kazuhiko Kido, PharmD, PhD, FCCP, BCPS, BCCP

Clinical Associate Professor

Organization:

West Virginia University School of Pharmacy

Department:

Clinical Pharmacy

Classification:

Clinical Faculty

• PharmD, The University of Iowa College of Pharmacy, 2013
• MS, Keio University Faculty of Pharmacy, 2009
• BS, Kyoritsu College of Pharmacy, 2007
• PhD, Kitasato University School of Pharmacy, 2021

Selected Publications

Kido K, Shimizu M, Shiga T, Hashiguchi M, Jalil B, Caccamo M, Sokos G. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with chronic thromboembolic pulmonary hypertension. Am J Cardiol. 2024 Jan. [Epub ahead of print]        

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2023 Nov. [Epub ahead of print]  

Kido K, Carey B, Caccamo M, Bianco C, Sokos G. Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy. J Am Pharm Assoc (2003). 2023 Oct. [Epub ahead of print]  

Kido K, Fang W, Broscious R, Colvin B, Kamal K, Bianco C, Caccamo M, Felpel K, Sokos G. Evaluating a pharmacists-providers collaborative iron deficiency treatment clinic in heart failure clinic. Am J Health Syst Pharm. 2023 March 27. Accepted.

Sokos G#, Kido K^#, Panjrath G, Benton E, Page R, Patel J, Smith P, Korous S, Guglin M. Multidisciplinary care in heart failure services. J Card Fail. 2023 Feb 7. Accepted. # co-primary author.

Kido K, Colvin BM, Szymanski TW, Guglin M. Sacubitril/valsartan off-label use for heart failure. J Card Fail. 2022;28:1185-1201.

Kido K, Colvin BM, Broscious R, Bongiorni S, Sokos G, Kamal KM. Economic impact of ambulatory clinical pharmacists in an advanced heart failure clinic. Ann Pharmacother. 2022 Feb 15. [Epub ahead of print]

Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. J Am Pharm Assoc (2003). 2021 Oct 27. [Epub ahead of print] 

Kido K, Bianco C, Caccamo M, Fang W, Sokos G. Association of body mass index with clinical outcomes in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. J Cardiovasc Pharmacol Ther. 2021 Jun 17. [Epub ahead of print].  

Kido K, Ghaffar YA, Lee JC, Bianco C, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. PLoS One. 2021;16:e0252549.    

Kido K, Bianco C, Caccamo M, Fang W, Sokos G. Evaluating sacubitril/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction. Ann Pharmacother. 2021;55:1069-1075. 

Brokmeier H, Kido K. Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review. Ann Pharmacother. 2021;55:995-1009.   

Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing direct oral anticoagulants versus warfarin in morbidly obese patients with atrial fibrillation. Am J Cardiol. 2020. April 8. [Epub ahead of print].

Kido K, Lee JC, Hellwig T, Gulseth MP. Direct oral anticoagulants in the morbidly obese. Pharmacotherapy. Accepted in Nov. 2019.

Kido K, Coons JC. Efficacy and safety of pulmonary arterial hypertension medications in patients with pulmonary hypertension due to left heart disease. Pharmacotherapy. Accepted in July 2019. 

Kido K, Shimizu M, Hashiguchi M. Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis. J Am Pharm Assoc (2003). 2019;59:432-438. 

Kido K, Oyen AA, Beckmann MA, Brouse SD. Musculoskeletal Toxicities of Patients Receiving Concomitant Statin and Daptomycin Therapy: Do statins need to be held while on daptomycin? Am J Health Syst Pharm. 2019;76:206-210.   

Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53:165-170.

Kido K, Guglin M. Anticoagulation therapy in specific cardiomyopathies: Isolated left ventricular noncompaction and peripartum cardiomyopathy. J Cardiovasc Pharmacol Ther. 2019;24:31-36. 

Kido K, Ball J. Optimal intensity of warfarin therapy in patients with mechanical aortic valves. J Pharm Pract. 2019;32:93-98.  

Kido K, Scalese MJ. Management of oral anticoagulation therapy after gastrointestinal bleeding: whether to, when to, and how to restart an anticoagulation therapy. Ann Pharmacother. 2017;51:1000-1007.

Kido K, Noyes E, Gutnik L. Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: A case report. J Clin Pharm Ther. 2017;42:631-633.

Kido K, George B, Charnigo RJ, Macaulay TE, Brouse SD, Guglin M. Chronological changes and correlates of loop diuretic dose in left ventricular assist device patients. ASAIO J. 2017;63:774-780.

Kido K, Evans RA, Gopinath A, Flynn JD. Severe hypertriglyceridemia induced by sirolimus treated with medical management without plasmapheresis. J Pharm Pract. 2018;31:104-106.

Noel ZR, Kido K, Macaulay TE. Selexipag for the treatment of Pulmonary Arterial Hypertension. Am J Health Syst Pharm. 2017;74:1135-1141.

Kido K, Guglin M. Drug-induced Takotsubo cardiomyopathy. J Cardiovasc Pharmacol Ther. 2017;22:552-563.

Kido K, Adams VR, Morehead RS, Flannery AH. Capecitabine induced ventricular fibrillation arrest: possible Kounis syndrome. J Oncol Pharm Pract. 2016;22:335-40.

Kido K, Brouse SD, Macaulay TE, Charnigo RJ, Anaya P. Dose related patterns of ventricular arrhythmia due to carvedilol withdrawal in patients with systolic heart failure. Curr Drug Saf. 2015;10:227-33

See Google Scholar for the publication list: https://scholar.google.com/citations?user=fQj40z0AAAAJ&hl=en

 

Dr. Kido is a clinical pharmacy associate professor at West Virginia University School of Pharmacy. Dr. Kido graduated from the University of Iowa College of Pharmacy in 2013 and completed PGY 1 pharmacy practice residency and PGY 2 cardiology pharmacy residency at the University of Kentucky HealthCare. He also received his Doctor of Philosophy from Kitasato University, Master of Science Degree from Keio University and a Bachelor of Science from Kyoritsu College of Pharmacy in Japan. Dr. Kido is a cardiology clinical pharmacy specialist in the WVU outpatient heart failure clinic and the WVU inpatient heart failure service. His practice interests are heart failure pharmacotherapy optimization, anticoagulation therapy, and IV iron therapy management. His primary teaching responsibilities include therapeutic lectures in cardiology and precepting fourth-year pharmacy students for APPE rotations. His teaching interests include interprofessional education, layered learning practice model, and simulation in pharmacy education. His research interests include anticoagulation in special populations, heart failure pharmacotherapy, and implementation science research. Dr. Kido has published multiple original research and review articles in peer-reviewed journals. In addition, he has presented at national and international conferences. He is an active member of the American College of Cardiology, American College of Clinical Pharmacy, American Society of Health-System Pharmacists, and Heart Failure Society of America. He served as a writing committee member for the ACC/AHA/ACCP/HRS atrial fibrillation guidelines.